Post Profile






Diplomat Sees Declining DIR Fee Impact—and Perhaps Readies a PBM Strategy

Last week, Diplomat Pharmacy released its quarterly earnings, which included new details about the financial impact of Direct and Indirect Remuneration (DIR) fees. I provide some background on DIR fees below. Diplomat, as a public company, is the only entity that is obligated to publish truthful information about DIR fees. While reviewing its data, let’s recall our Drug Channels philosophy, courtesy of the late senator Daniel Patrick Moynihan: "Everyone is entitled to his own opinion, but not his own facts.
read more

share

Related Posts


Drug Channels Earnings Calendar: 2011:Q1

Medical / Pharmaceutical : Drug Channels

The largest drug wholesalers and Pharmacy Benefit Managers (PBMs) all report quarterly financial results for the first calendar quarter of 2011 this week and next week. These financial reports and accompanying conference calls provi...

Express Scripts Talks About Its Pure-Play PBM Strategy, Deals Not Done, and Walgreens

Medical / Pharmaceutical : Drug Channels

Yesterday, Express Scripts held its latest quarterly call. (See links below for materials.) Along with the usual corporate yada yada yada, the call provided intriguing insights about Express Scripts' strategy and the PBM business mo...

DIR Fees, Rebates, Pharmacy Economics, and the Future of Medicare Part D (rerun)

Medical / Pharmaceutical : Drug Channels

DIR Fees, Rebates, Pharmacy Economics, and the Future of Medicare Part D This week, I’m rerunning some popular posts while I attend Asembia’s 2017 Specialty Pharmacy Summit. Click here to see the original post and comments from Febr...

Behind Diplomat Pharmacy’s Plunge: A Primer on DIR Fees in Medicare Part D

Medical / Pharmaceutical : Drug Channels

Last week, Diplomat Pharmacy became the latest high-profile drug channel company to see its shares take a high-profile dive. The specialty pharmacy’s stock dropped by 45%, falling below the IPO offering price. Look out below! Diplom...

DIR Fees, Rebates, Pharmacy Economics, and the Future of Medicare Part D

Medical / Pharmaceutical : Drug Channels

The Centers for Medicare & Medicaid Services (CMS) just released a controversial and important new report: Medicare Part D – Direct and Indirect Remuneration (DIR). The report shows mixed consequences of DIRs in the Medicare Part D ...

Comments


Copyright © 2016 Regator, LLC